United Therapeutics Corporation Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
United Therapeutics Corporation (UTHR) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2026-02-25
- United Therapeutics Corporation impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2022-12-31 was $0.00.
- United Therapeutics Corporation impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2022-09-30 was $0.00.
- United Therapeutics Corporation impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2022-06-30 was $0.00.
- United Therapeutics Corporation impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- United Therapeutics Corporation impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2025 was $0.00.
- United Therapeutics Corporation impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2024 was $0.00.
- United Therapeutics Corporation impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2023 was $0.00.
- United Therapeutics Corporation impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-25 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $0.00 10-Q · filed 2022-11-02 | $0.00 derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $0.00 10-Q · filed 2022-08-03 | $0.00 derived: sum of 3 quarters · filed 2024-02-21 | $0.00 derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 | $0.00 derived: sum of 2 quarters · filed 2024-02-21 | $0.00 derived: sum of 3 quarters · filed 2024-02-21 | $0.00 derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $0.00 derived: sum of 2 quarters · filed 2024-02-21 | $0.00 derived: sum of 3 quarters · filed 2024-02-21 | $113.40M 10-K · filed 2024-02-21 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $113.40M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $113.40M 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | $113.40M 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-22 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-02-26 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-02-27 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-02-21 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |